} .hero h1{ color: $lt-green; font-weight: 400; font-size: 10px; @media (max-width: 991px) { font-size: 10px; font-weight: 500; } } EIP Pharma: treating neurodegenerative diseases

We believe the key to treating neurodegenerative disease is to intervene early.

Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking. Their ability to go about their daily lives is impacted by these progressive conditions. We believe that by applying our approach we can reverse the synaptic dysfunction that, ahead of death of nerve cells, is responsible for disease symptoms and progression.

Corporate Presentation

A FOCUS ON

Neurodegenerative Disease

Dementia with Lewy Bodies

Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain’s nerve cells. This negatively affects both cognitive ability - including attention, judgement, and reasoning – and motor function.

Alzheimer’s Disease

Alzheimer’s disease is a condition characterized by memory loss, disorientation and other cognitive deficits that worsen as the disease progresses.

Stroke Recovery

Stroke, caused by blockage of arteries supplying blood to the brain, is the number one cause of long-term disability in adults. Most stroke survivors have some level of recovery after a stroke. However, in moderately severe and severe stroke the recovery is often incomplete.

 EIP Pharma's Approach for Dementia with Lewy Bodies

     

Hope Through Science

Introducing Neflamapimod

We’re developing neflamapimod—an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical data with neflamapimod, along with evidence from recent phase 2 clinical studies in dementia with Lewy bodies (DLB) and in Alzheimer’s disease (AD), strongly suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies disease progression in the early stages of many neurological disorders.

Treatment & Results

EIP Pharma in the News

EIP Pharma to Present at JMP Securities Life Sciences Conference

May 11, 2023

EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023

April 3, 2023

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

March 30, 2023


News & Events